SERMs to help prevent postmenopausal bone loss in women

Published: 2004-08-31 06:58:00

Updated: 2004-08-31 06:58:00

An imbalance in the bone remodeling cycle caused bone loss that eventually leads to osteoporosis and fracture risk, and among selective estrogen-receptor modulators (SERMs), raloxifen (Evista) may be considered an effective alterative for the prevention of postmenopausal bone loss in women, accor...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK